HT-102

Phase 1Small molecule

SSuzhou HepaThera Biotech Co., Ltd.

HT-102 is one of 72 small molecule programs targeting Chronic Hepatitis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic HepatitisActive, not recruiting

Chronic Hepatitis B Virus InfectionActive, not recruiting

Chronic HepatitisPhase 1

Active, not recruiting

Chronic Hepatitis B Virus InfectionPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

624 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

PEG-Intron

Merck & Co.

Preclinical

43 2

Sovaldi

Gilead

Preclinical

34 3

Incivek

Vertex Pharmaceuticals

Preclinical

10 4

Intron a

Sanofi

Preclinical

7 5

Roferon-a

Roche

Preclinical

3 6

Medrol

Pfizer

Preclinical

1 7

Dasabuvir

AbbVie

Preclinical

7 8

SOF/VEL

Gilead

Preclinical

4 9

Keyhole-Limpet Hemocyanin

Bristol-Myers Squibb

Preclinical

1 10

Pegintron

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Chronic Hepatitis B Virus Infection

NCT07245953

Phase 1/2Active, not recruiting

Chronic Hepatitis B Virus Infection

NCT07183306

Clinical

Trials by Indication[1]

Chronic Hepatitis B Virus Infection2 trials

A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection

Active, not recruiting·SSuzhou HepaThera Biotech Co., Ltd.·Phase 2·NCT07245953·60 enrolled

A Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus Infection

Active, not recruiting·SSuzhou HepaThera Biotech Co., Ltd.·Phase 1/2·NCT07183306·86 enrolled

Chronic Hepatitis1 trial

Phase 1 Study of HT-102 Administered Subcustaneously in Healthy Participants and Patients with Chronic Hepatitis B for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity (only in Participants with Chronic HBV Infection)

Completed·SSuzhou HepaThera Biotech Co., Ltd.·Phase 1·NCT06744686·56 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for HT-102. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HT-102 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HT-102. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Suzhou HepaThera Biotech Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SSuzhou HepaThera Biotech Co., Ltd.

HT-102

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Chronic Hepatitis B Virus Infection2 trials

Chronic Hepatitis1 trial

References

Drug Info

Quick Facts

Related News